| página 44-46 |
Referencias
1.Amirav I, Burg F. The need to educate health professionals about
childhood asthma. Arch Pediatr Adolesc Med 1994;148: 1339-1343.
2. Weiss KB, Gergen PJ, Wagener DK. Breathing better or wheezing worse?
The changing epidemiology of asthma morbidity and mortality. Ann Rev Publ
Health 1993; 14: 491-513.
3. Baeza-Bacab MA, Sienra-Monge JJL. Asma: inflamación e hiperreactividad
bronquial. Bol Med Hosp Infant Mex 1993; 50:832-836.
4. National Heart, Lung, and Blood Institute. Guidelines for the diagnosis
and management of asthma. I. Definition and diagnosis. J Allergy Clin Immunol
1991; 88: 427-438.
5. Blair H. Natural history of childhood asthma. Arch Dis Child 1977;
52: 613-618.
6. Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan
WJ y col. Asthma and wheezing in the first six years of life. N Engl J
Med 1995; 332: 133-138.
7. Gergen PJ, Mullally DI, Evans R III. National Survey of prevalence
of asthma among children in the United States 1976-1980. Pediatrics 1988;
81: 1-7.
8. Evans R, Mullally DI, Wilson RW. National trends in asthma:morbidity
and mortality of asthma in the United States. Chest 1987; 91: 658.
9. Robertson CF, Heycock E, Bishop J, Nolan T, Olinsky A, Phelan PD.
Prevalence of asthma in Melbourne schoolchildren: changes over 26 years.
BMJ 1991; 302:1116-1118.
10. Caraballo L, Cadavid A, Mendoza J. Prevalence of asthma in a tropical
city of Colombia. Ann Allergy 1992; 68:525- 529.
11. Fritscher CC, Severo RD, Fagondes SC, Cohen R, Dornelles RL, Kahan
F. Modificacoes na prevalencia de asma bronquica em escolares de Porto
Alegre. J Pneumol 1994; 20:6-10.
12. Baeza-Bacab MA, Graham-Zapata LF. Pre valencia del asma. Encuesta
en una población escolar de Villahermosa, Tabasco,México.
Aler gia 1992; 39:32-36.
13. González-Gamez JG, Barrera-Gómez LE, Arévalo-Orozco
MA. Prevalencia del asma bronquial en la ciudad de Guadalajara,Jal., México.
Alergia 1992; 39:3-7.
14. Hopp RJ, Townley RG, Biven R, Bewtra AK, Nair NM. The presence of
airway reactivity before the development of asthma. Am Rev Respir Dis 1990;
141: 2-8.
15. Postma DS, Bleecker ER, Amelung PJ, Holroyd KJ, Xu J, Panhuysen
CIM y col. Genetic susceptibility to asthma-bronchial hyperres ponsiveness
coinherited with a major gene for atopy. N Engl J Med 1995; 333: 894-900.
16. Van asperen PP, Kemp AS. The natural history of IgE sensitization
and atopic disease in early childhood. Acta Paediatr Scand 1989; 78: 239
-245.
17. Martin AJ, McLennan LA, Landau LI, Phelan PD. The natural history
of childhood asthma to adult life. BMJ 1980; 280:1397-1400.
18. Nelson HS. The natural history of asthma. Ann Allergy 1991;66: 196-203.
19.Center for Diseases Control. Asthma-United States, 1980-1990. MMWR
1992; 41: 733-735.
20. Salas RM,Segura MNH, Martínez-Cairo CS. Tendencia de la mortalidad
por asma en Méxi co. Bol Of Sanit Panam 1994; 116:298-306.
21. Hargreave FE, Dolovich J, O'Byrne PM, Ramsdale EH, Daniel EE.The
origin of airway hyperresponsiveness. J Allergy Clin Immunol 1986; 78:
825-832.
22. Woolcock AJ, Salome CW, Yan K. The shape of the dose-response curve
to histamine in asthmatic and normal subjects. Am Rev Respir Dis 1984;
130: 71-75.
23. Creticos PS. Immunotherapy in asthma. J Allergy Clin Immunol 1989;
83: 554-562.
24. Nsouli TM, Nsouli SM, Bellanti JA. Neu roimmunoallergic inflammation:
new pathogenetic concepts and future perspectives of immediate and late
allergic reactions: part I. Ann Allergy 1988; 60: 379-389.
25. Barnes PJ. Allergic inflammatory mediators and bronchial hyperresponsiveness;
an introductory overview. Immunol Allergy Clin North Am 1990; 10:241-249.
26. Kaliner M. Asthma and mast cell activation. J Allergy Clin Immunol
1989; 83: 510-520.
27. Kawalsky M, Didier A, Kaliner M. Neurogenic inflammation in the
airways. Am Rev Respir Dis 1989; 140: 101-109.
28. Wennergren G, Kristjánsson S, Strannegard IL. Decrease in
hospitalization for treatment of childhood asthma with increased use of
antiinflammatory treatment, despite an increase in the prevalence of asthma.
J Allergy Clin Immunol 1996; 742-748.
29. Larsen GL. Late-phase reactions: observations on pathogenesis and
prevention. J Allergy Clin Immunol 1985; 76: 665-669.
30. Köning P. Diagnostic problems in asthma. Ann Allergy 1985;
55: 95-102.
31. Venegas M, Molina C, Arana A, Baeza M, Cuevas F y col. Consenso
Latinoamericano sobre Diagnóstico y Tratamiento del Asma. Diagnóstico
del asma. Alergia 1994; 41 (supl): s9- s11.
32. Howard WA. Differential diagnosis of wheezing in children. Pediatr
Rev 1980; 1: 239-244.
33. Eigen H. The clinical evaluation of chronic cough. Pediatr Clin
North Am 1982; 29: 67-68.
34. American Board of Pediatrics. Asma. Pediatr Rev 1992 (supl): 11-12.
35. National Heart, Lung, and Blood Institute. Guidelines for the diagnosis
and management of asthma. VIII. Management of acute exacerbations of asthma.
J Allergy Clin Immunol 1991; 88:493518.
36. Polgar G, Promedhat V. Pulmonary function testing in children:techniques
and standards. Filadelfia: W.B. Saunders, 1971.
37. McFadden ER. Clinical physiologic correlates in asthma. J Allergy
Clin Immunol 1986; 77: 1-5. <-- Generaci—n de la p‡gina 45 del documento PM -->
38. Rebuck AS, Pengelly D. Development of pulsus paradoxus in the presence
of airways obstruction. N Engl J Med 1973; 288:66-69.
39. National Heart, Lung, and Blood Institute. Guidelines for the diagnosis
and management of asthma. II. Objective measures of lung function. J Allergy
Clin Immunol 1991; 88: 439-446.
40. Cross D, Nelson HS. The role of the peak flow meter in the diagnosis
and management of asthma. J Allergy Clin Immunol 1991; 87;120 -128.
41. American Academy of Pediatrics. Practice parameter: the office management
of acute exacerbations of asthma in children. Pediatrics 1994; 93: 119-126.
42. Sienra-Monge JJL, Baeza-Bacab MA, Serra no-Sierra A.Tratamiento
del asma. Bol Med Hosp Infant Mex 1995; 52: 443-450.
43. Hendeles L, Harman E, Huang D, O'Brien R, Blake K, Delafuente J.
Theophylline attenuation of airway responses to allergen: comparison with
cromolyn metereddose inhaler. J Allergy Clin Immunol 1995; 95: 505514.
44. FernandezCaldas E, Fox RW. Control am biental de contaminación
del aire en interio res. Clin Med Norteam 1992; 76:973994.
45. Solomon WR. Prevention of allergic di sorders.Pediatr Rev1994;5:301-309.
46. Duff AL, PlattsMills TAE. Alergenos y asma. Clin Pediatr Norteam
1992; 39:13691383.
47. WilliamsGotti M, SienraMonge JJL, del RioNavarro B. Respuesta cutánea
al alergeno de la cucaracha en pacientes alérgicos. Alergia 1991;
38: 139143.
48. Holbreich M. Allergic and irritant triggers of asthma. En: Bukstein
DA, Strunk RC, ed. Manual of clinical problems in asthma,allergy, and related
disorders. Boston: Little, Brown and Company, 1985:110117.
49. National Heart, Lung, and Blood Institute. Guidelines for the diagnosis
and management of asthma. VI. Managing allergy in the asthma patient. J
Allergy Clin Immunol 1991; 88:473476.
50. Organización Mundial de la Salud. Estado actual de la inmunoterapia
con alergenos. Bol Of Sanit Panam 1989; 106: 531-546.
51. Joint Task Force on Practice Parameters, American Academy of Allergy,
Asthma and Immunology, American College of Allergy, Asthma and Immunology.
Practice parameters for the diagnosis and teatment of asthma. VI. Asthma
management. J Allergy Clin Immunol 1995; 96:749-820.
52. Zeiger RS. Atopy in infancy and early childhood: natural history
and role of skin testing. J Allergy Clin Immunol 1985; 75: 633- 639.
53. Aguilar-Amézquita JE. A favor de la in munoterapia. Alergia
1991; 38: 79-84.
54. Nelson HS. b-adrenergic bronchodilators. N Engl J Med 1995; 333:
499-506.
55. American Academy of Allergy and Immunology. Inhaled b2adrenergic
agonists in asthma. J Allergy Clin Immunol 1993; 91:12341237.
56. Brogden RN, Faulds D. Salmeterol xinafoate. A review of its pharmacological
properties and
therapeutic potential in reversible obstructive airways disease. Drugs
1991; 42:118.
57. BaezaBacab MA, SienraMonge JJ. Trata miento del asma aguda. Bol
Med Hosp Infant Mex 1987; 44:239244.
58. Sly RM. Sympathomimetics in the treat ment of asthma. Clin Proc
CHNMC 1983; 39:256270.
59. Larsson S, Stiksa G. Different inhalation forms in the treatment
of bronchial asthma. En: Pharmacological treatment of bronchial asthma.
Estocolmo: National Board of Health and Welfare Drug Committee, 1986:8393.
60. Canny GJ, Levison H. Aerosoltherapeutic use and delivery in childhood
asthma. Ann Allergy 1988;60:1119.
61. DelRioNavarroBE, SienraMonge JJL, BriceñoPérez C,
PrietoUrzua L, Pare desNovelo C. Estudio comparativo de tres diferentes
dosis de salbutamol inhalado en el manejo inicial de crisis asmática
en niños. Bol Med Hosp Infant Mex 1994; 51:650655.
62. National Heart, Lung, and Blood Institute. Guidelines for the diagnosis
and management of asthma. IV.Overview of approaches to asthma therapy.
J Allergy Clin Immunol 1991; 88:451459.
63. Burrows B, Lebowitz MD. The bagonist dilemma. N Engl J Med 1992;
326: 560561.
64. Sears MR. Increasing asthma mortality: fact or artifact? J Allergy
Clin Immunol 1988; 82:957960.
65. Rooklin A. Theophylline: is it obsolete for asthma? J Pediatr 1989;
115:841845.
66. Kraznowski JJ, Polson JB. Mechanism of action of methylxanthines
in asthma. J Allergy Clin Immunol 1988;82:143145.
67. Hendeles L, Massanari M, Weinberger M.Teofilina. En: Middleton E
Jr,Reed CE, Ellis EF, Adkinson NF, Yunginger JW, ed: Alergia principios
y práctica. 3a. ed. Barcelo na: Salvat Editores,S.A., 1992:631669.
68. Weiberger M, Hendeles L. Theophylline in asthma. N Engl J Med 1966;
334: 1380-1388.
69. Bukstein DA, Theophylline. En: Bukstein DA, Strunk RC, ed: Manual
of clinical problems in asthma, allergy, and related disorders. Boston:
Little,Brown and Company, 1984:147153.
70. Crescioli S, Spinazzi A, Olebani M y col. Theophylline inhibits
early and late asthmatic reactions induced by allergens in asthmatic subjects.
Ann Allergy 1991;66:245351.
71. Nassif EG, Weinberger MM, Shannon D y col. Theophylline disposition
in infancy. J Pediatr 1981; 98:158161.
72. Malka S, Sienra JJ, García-Caballero R, Mo reno-Gardea H,
Gómez-Orozco L, Huerta-López J y col. Consenso Latinoamericano
so bre Diagnóstico y Tratamiento del Asma. Diag nóstico del
asma. Tratamiento del niño asmá tico. Alergia 1994; 41(supl):
s12s15.
73. Gross NJ. Ipatropium bromide. N Engl J Med 1988;319: 486494.
74. BaezaBacab MA. Tratamiento del asma. I. Agentes antiasmáticos:
cromoglicato de sodio y nedocromil sódico. Rev Biomed 1992; 3:1319.
75. SienraMonge JJ, BaezaBacab MA, CasillasJimenez R,CavazosGalván
M, del RealSánchez H. Uso de cromoglicato de sodio <-- Generaci—n de la p‡gina 46 del documento PM -->
por nebulizaciones en niños asmáticos meno res de siete
años. Alergia 1990; 37:712.
76. Kay AB, Walsh GM, Moqbel R y col. Disodium cromoglycate inhibits
activation of human inflammatory cell in vitro. J Allergy Clin Immunol
1987; 80:18.
77. Koning P. The role of cromolyn sodium in the treatment of asthma.
Prac Cardiol 1987; 13:8997.
78. McFadden ER, Gilbert IA. Exercise induced asthma. N Engl J Med 1994;
330:13621367.
79. Settipane GA. Adverse reaction to cromolyn. JAMA1986; 241: 811813.
80. Clark B. General pharmacology, phar macokinetics, and toxicology
of nedocromil sodium. J Allergy Clin Immunol 1993; 92:200202.
81. Fould S R. An overview of human safety data with nedocromil sodium.
J Allergy Clin Immunol 1993; 92:202204.
82. Furukawa CT. Antiasthma agents. Cromolyn sodium and nedocromil sodium.
Immunol Clin North Am 1990; 10:503514.
83. Cherniack RM, Wasserman SI, Ramsdell JW y col.A doubleblind multicenter
group comparative study of the efficacy and safety of nedocromil sodium
in the management of asthma. Chest 1990; 97:12991306.
84. Schwartz HJ, Kemp JP, Bianco S y col. Highlights of the nedocromil
sodium clinical study presentations. J Allergy Clin Immunol 1993; 92: 204209.
85. Callaghan B, Teo NC, Clancy L. Effects of the addition of nedocromil
sodium to maintenance bronchodilator therapy in the management of chronic
asthma. Chest 1992; 101:787792.
86. BaezaBacab MA. Tratamiento del asma. II. Agentes antiinflamatorios.
Rev Biomed 1993; 4:1925.
87. Goldenhersh MJ, Spector SL. Corticoesteroid use in pediatric asthma.
Am J Asthma Allergy Pediatr 1989; 3:817.
88. Woolcock AJ, Jenkins C. Corticoesteroids in the modulation of bronchial
hiperresponsiveness. Immunol Allergy Clin North Am 1990; 10:543557.
89. Barnes PJ, Pedersen S. Efficacy and safety of inhaled corticoesteroid
in asthma. Am Rev Respir Dis 1993; 148: S1S26.
90. Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med 1995;
332: 869-875.
91. Koning P. Inhaled corticoesteroid their present and future role
in the management of asthma. J Allergy Clin Immunol 1988; 82:297306.
92. American Academy of Allergy and Immunology, Committee on Drugs.
The use of antihistamines in patients with asthma. J Allergy Clin Immunol
1988; 82: 481-482.
93. Kemper KJ. Chronic asthma: an update. Pediatr Rev 1996; 17: 111-117.
94. Kong X-T, Fang HT, Jiang GQ. Treatment of acute bronchiolitis with
Chinese herb. Arch Dis Child 1993; 68: 468-471.
95. Collipp PJ, Goldzier S, Weiss N. Pyridoxine treatment of childhood
bronchial asthma. Ann Allergy 1975; 35: 93-97.
96. Dorsch W, Wagner H. New anti-asthmatic drugs from traditional medicine?
Int Arch Allergy Appl Immunol 1991: 94: 262-265.
97. Reilly D, Taylor MA, Beattie NGM. Is evidence for homeopathy reproducible?
Lancet 1994; 344: 1601-1606.
98.Joint Task Force on Practice Parameters, American Academy of Allergy,
Asthma and Immunology, American College of Allergy, Asthma and Immunology.
Practice parameters for the diagnosis and treatment of asthma. IV. Consultation
with an specialist. J Allergy Clin Immunol 1995; 96:729-731.
99. Baeza-Bacab MA, Sienra-Monge JJ. El niño asmático
y los deportes. Bol Med Hosp Infant Mex 1987; 44:283-286.
100. National Heart, Lung, and Blood Institute. Guidelines for the diagnosis
and management of asthma. IX. Exercise-induced asthma. J Allergy Clin Immunol
1991; 88:519522.
101. Jamgochian M. Physical education and the child with asthma. Am
J Asthma Allergy Pediatr 1990; 3:97-100.
102. Hannaway PJ, Hopper DK. Cough variant asthma in children.JAMA 1982;
247: 206 -208.
103. O'Connell EJ, Rojas AR, Sachs MI. Cough -type asthma: a review.
Ann Allergy 1991; 66: 278-282.
104. McFadden ER. Exertional dyspnea and cough as preludes to acute
attacks of bronchial asthma. N Engl J Med 1975; 292: 555-559.
105. National Heart, Lung, and Blood Institute. Guidelines for the diagnosis
and management of asthma. VII. Management of asthma. J Allergy Clin Immunol
1991; 88:477492.
106. Herbest JJ, Minton SD, Bool LS. Gas troesophageal reflux causing
respiratory distress and apnea in newborn infant. J Pediatr 1979; 763-768.
107. Herve P, Dejean A. Intraesophageal perfusion of acid increases
the bronchomotor response to metacholine and to isocapnic hiper ventilation
in asthmatic subjects. Am Rev Respir Dis 1986; 134:986- 991.
108. Ekstrom T, Tibbling L. Esophageal acid perfusion airway function
and symptoms in asthma patients with marked bronchial hiperreactivity.
Chest 1989; 96: 995-998.
109. Mansfield LE, Hameister HH, Spaulding HS. The role of the vagus
nerve in airway narrowing caused by intraesophageal hydrocloric acid provocation
and esophageal distention. Ann Allergy 1981; 47:431-434.
110. Korzaker RA. Complications of reflux eso phagitis and their medical
management. Gastroenterol Clin North Am 1990;19: 713 -731.
111. McCauley RG, Darling DB, Leonindas JC. Gastroesophageal reflux
in infant and children: A useful classification and reliable physiologic
technique or its demonstration. Am J Radiology 1978; 130:47-50.